To date, ozenoxacin has been used in trials studying the treatment of impetigo.
As of December 11, 2017 the FDA approved Ferrer Internacional S.A.'s Xepi (ozenoxacin 1%) as a topically applied cream indicated for the treatment of impetigo caused by Staphylococccus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older.
...
Ozenoxacin cream is indicated for the topical treatment of impetigo caused by Staphylococcus aureus or Streptococcus pyogenes in patients aged 2 months of age and older .
Caparra Internal Medicine Center, Rio Grande, Puerto Rico
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.